Wednesday, July 8, 2026

Patent intelligence · US

US 11576971

Method of filling a container with no headspace

granted A61KA61K39/39591A61K47/02A61K47/183
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 17
Applicant portfolio 73
Patent details — US 11576971
Jurisdiction
US
Status
granted
Grant date
Feb 14, 2023
Expiration
Feb 9, 2043
Claims
13
CPC classes
A61K, A61K39/39591, A61K47/02, A61K47/183
View on Google Patents ↗

Quick answer

US 11576971 (Method of filling a container with no headspace) is held by Coherus BioSciences, Inc.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K39/39591, A61K47/02, A61K47/183, A61K9/0019, A61K9/08

More from Coherus BioSciences, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11667702

    Stable aqueous formulations of aflibercept

    Coherus BioSciences, Inc. · Expires Jun 1, 2043

    granted
  2. US 11583584

    Stable protein compositions and methods of their use

    Coherus BioSciences, Inc. · Expires Feb 16, 2043

    granted
  3. US 11426446

    Stable aqueous formulations of aflibercept

    Coherus BioSciences, Inc. · Expires Aug 25, 2042

    granted
  4. US 11400072

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Coherus BioSciences, Inc. · Expires Jul 28, 2042

    granted
  5. US 11396540

    Methods for making recombinant proteins

    Coherus BioSciences, Inc. · Expires Jul 21, 2042

    granted
  6. US 11253508

    PPARy agonist for treatment of progressive supranuclear palsy

    Coherus BioSciences, Inc. · Expires Feb 17, 2042

    granted
  7. US 11229702

    High concentration formulations of adalimumab

    Coherus BioSciences, Inc. · Expires Jan 20, 2042

    granted

Frequently asked questions

What is US patent 11576971?

US 11576971 (Method of filling a container with no headspace) is held by Coherus BioSciences, Inc.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11576971?

Coherus BioSciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 73 pharmaceutical patents for this assignee.

When does US 11576971 expire?

Our index shows an expiration date of Feb 9, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.